Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomized clinical trial

Hamilton, S.H.; Edgell, E.T.; Revicki, Dennis A.; Genduso, L.A.; Tollefson, G.D.

doi:10.1016/s0924-977x(98)80406-9

Cited by 36 publications

(66 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent findings also substantiate the general notion that novel antipsychotic medications are uniformly better tolerated as indicated by the measures of self-rated quality of life [5,[23][24][25][26]. If these pharmacological properties are shown to be significant, the therapeutic implications could be far reaching in terms of improved compliance, relapse prevention, effective rehabilitation and enhanced quality of life [13,16,19,25,27]. There has been a growing need, however, not only to establish the therapeutic superiority of more recently developed medications over the conventional antipsychotic drugs, but also to explore the differential effectiveness of various individual compounds and their influence on the patients' subjective well-being [26,[28][29][30].…”

Section: Introductionmentioning

confidence: 60%

“…The success of novel antipsychotics would eventually depend on three key issues: subjective tolerability of the drugs, their impact on an individual's quality of life, and cost [13,14]. Clinical trials suggest that new antipsychotic drugs are less likely to induce extrapyramidal side effects [15][16][17][18] and may even be better suited to alleviate negative symptoms [19] and neurocognitive deficits associated with schizophrenia [20][21][22].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Flupenthixol versus Risperidone: Subjective Quality of Life as an Important Factor for Compliance in Chronic Schizophrenic Patients

et al. 2003

View full text Add to dashboard Cite

Objective: The primary aim of this paper was to compare the effects of flupenthixol and risperidone on subjective quality of life and attitude towards medication in chronic schizophrenic patients with mainly negative symptoms. In a spectrum ranging from its typical end ‘haloperidol’ to its atypical end ‘clozapine’, flupenthixol has typical and atypical characteristics. Methods: The effects of flupenthixol versus risperidone were investigated in a multicenter, double-blind trial, whereas subjective quality of life was assessed by means of the EuroQuol-Visual Analogue Scale and the patient satisfaction questionnaire. The attitude towards medication was assessed by means of the Drug Attitude Inventory-30 (DAI-30). Results: Mean daily dose of study medication was 6.6 (SD 2.9) mg/day flupenthixol and 3.6 (SD 1.2) mg/day risperidone. Both groups showed a significant improvement regarding subjective quality of life and positive attitude towards medication. Especially the categories ‘control of their thoughts’, concentration and ‘feeling better in general’ ameliorated in both groups. In the flupenthixol group, the ‘ability to cope with stress’, ‘feel more relaxed’ and the ‘ability to achieve something’ improved significantly more than in the risperidone group. Conclusions: (1) The spectrum of schizophrenia can be treated effectively with different neuroleptic treatments. (2) Flupenthixol especially improves the ability to cope with stress, the ability to achieve something and feeling more relaxed. (3) Subjective quality of life significantly increased with no difference between the groups.

show abstract

Section: Introductionmentioning

confidence: 60%

Section: Introductionmentioning

confidence: 99%

Flupenthixol versus Risperidone: Subjective Quality of Life as an Important Factor for Compliance in Chronic Schizophrenic Patients

et al. 2003

View full text Add to dashboard Cite

show abstract

“…As a first step, two Cochrane systematic reviews have clearly shown the superiority but limited acceptability of older anti-psychotic drugs such as chlorpromazine or haloperidol over placebo (Thornley et al, 2001;Joy et al, 2001), while the arrival of so-called atypical antipsychotics has made available to patients and clinicians a set of pharmacological treatment options that are no less efficacious and somewhat more tolerable. There is also now an accumulation of evidence that clearly demonstrates cost-effectiveness in randomised trials (e.g, see Essock et al, 2000;Hamilton et al, 1999;Rosenheck et al, 1999). The economic evidence for psychosocial interventions is less prevalent -mainly because few studies have yet been completed -but there are positive findings that point to the cost-effectiveness of family interventions to reduce the impact of family stress and conflict often seen in households with high expres-sed emotion (Xiong et al, 1994) and of a short psychoeducational programme to improve patient adherence with medication recommendations (Healey et al, 1998).…”

Section: The Effectiveness and Cost-effective-ness Of Schizophrenia Tmentioning

confidence: 99%

The economics of schizophrenia care in Europe: the Epsilon study

Chisholm

Knapp

2002

Epidemiol Psichiatr Soc

View full text Add to dashboard Cite

“…Questo dato è coerente i risultati di altri studi che hanno confrontato i costi della terapia con olanzapina e aloperidolo e che hanno dimostrato come i minori costi di ricovero dei pazienti in terapia con olanzapina ne possono compensare i maggiori costi di acquisizione (11,12,14). Questa marcata differenza nei costi dell'ospedalizzazione è responsabile dei minori costi del trattamento non farmacologico e di un trend verso costi totali di trattamento inferiori per i pazienti del gruppo a switch precoce rispetto a quelli del gruppo a switch tardivo.…”

Section: Tabellaunclassified

“…Numerosi studi di farmacoeconomia hanno però concordemente mostrato che la maggiore efficacia dei nuovi antipsicotici, inclusa la olanzapina, comporta una riduzione dei ricoveri e di altre voci di spesa che bilancia e supera i più alti costi di acquisizione (11,12,13,14,15).…”

Section: Introduzioneunclassified

Costi del trattamento con oloprazina nelle fasi iniziali della schizofrenia

Berardi

Dell’Atti

Russo

et al. 2002

View full text Add to dashboard Cite

INTRODUZIONEI nuovi antipsicotici hanno consentito un significativo progresso nel trattamento farmacologico della schizofrenia. In particolare, la olanzapina è più efficace dell'aloperidolo sia in termini di miglioramento clinico globale che nel trattamento dei sintomi negativi, depressivi e cognitivi (1, 2, 3). Inoltre, la olanzapina comporta un rischio significativamente ridotto di sintomi extrapiramidali e sintomi da iperprolattinemia (1, 2, 4, 5), ma causa altri effetti collaterali, tra cui aumento di peso (1, 2). I nuovi antipsicotici possono essere particolarmente vantaggiosi nelle fasi iniziali della schizofrenia. Sanger et al (6) hanno infatti mostrato che mentre tra i casi con schizofrenia cronica olanzapina è solo moderatamente più efficace dell'aloperidolo sui sintomi positivi, la differenza di efficacia diviene invece più ampia e statisticamente significativa nei pazienti con schizofrenia in fase di esordio. Studi recenti, inoltre, hanno dimostrato che gli antipsicotici di nuova generazione possono migliorare sostanzialmente la prognosi se utilizzati precocemente (7,8,9,10).A fronte di tali vantaggi, i nuovi antipsicotici presentano un costo di acquisizione marcatamente più elevato dei neurolettici tradizionali, determinando un aumento della spesa farmaceutica.Numerosi studi di farmacoeconomia hanno però concordemente mostrato che la maggiore efficacia dei nuovi antipsicotici, inclusa la olanzapina, comporta una riduzione dei ricoveri e di altre voci di spesa che bilancia e supera i più alti costi di ICERCA ORIGINALE ABSTRACTObjective: In Italy, use of olanzapine in the public sector was limited by law to patients that had failed treatment with conventional antipsychotics, due to the higher purchase price of the drug. This restriction prevented first-episode patients and patients early in the course of their illness from being treated with olanzapine. The present study investigates economic consequences of this policy. Design: The present study retrospectively outlines treatment costs of patients switched to olanzapine during the early stages of schizophrenia as compared to the costs of patients switched during a later stage of the illness. Setting: The study was conducted within Italian Community Mental Health Services. Patients: The cost of pharmacological and non-pharmacological treatment was retrospectively calculated in 25 out-patients with schizophrenia and related disorders over a one-year span. Thirteen patients were switched to olanzapine in the early stage of their illness, prior to drug approval under a compassionate use regimen. Twelve patients started olanzapine under the restriction in a later stage of illness following failed treatment with a conventional antipsychotic. Results: While total treatment costs between the two groups was similar, cost distribution was different. Early Switch patients had higher drug costs and higher rehabilitation costs, while Late Switch patients had higher hospitalisation costs. Conclusions: Small patient numbers and design limitations prevent conclusion...

show abstract

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomized clinical trial

Cited by 36 publications

References 0 publications

Flupenthixol versus Risperidone: Subjective Quality of Life as an Important Factor for Compliance in Chronic Schizophrenic Patients

Flupenthixol versus Risperidone: Subjective Quality of Life as an Important Factor for Compliance in Chronic Schizophrenic Patients

The economics of schizophrenia care in Europe: the Epsilon study

Costi del trattamento con oloprazina nelle fasi iniziali della schizofrenia

Contact Info

Product

Resources

About